Sam is a trader and one of our lead stock analysts at AskTraders. After starting his career predominantly in the forex markets, Sam now focuses on gold and stocks with a preference for macroeconomic analysis.
Shares of biopharmaceutical company MediciNova (NASDAQ: MNOV) are rallying premarket on Wednesday following the company’s announcement that it has partnered with the Biomedical Advanced Research and Development Authority (BARDA).
The partnership with BARDA, which is part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, will see them repurpose MN-166 (ibudilast) as a potential medical countermeasure against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).
BARDA will provide funding for proof-of-concept studies of MN-166 in preclinical models of chlorine gas-induced acute lung injury.
“Considering that pulmonary edema is a hallmark feature of exposure to chlorine, MN-166 has the potential to improve health outcomes and save lives,” commented Kazuko Matsuda, Chief Medical Officer of MediciNova.
“To date, more than 800 research participants have been treated with high-dose MN-166 in MediciNova’s clinical trials. MN-166 has shown a benign safety and tolerability profile,” added Matsuda.
Following the Tuesday evening announcement, MediciNova’s share price is trading 86% higher at $10.57 per share.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .